Meet the team

Randeep Grewal is a London-based ex-Fund manager with over 17 years of Healthcare investment experience including at Trium, F&C Asset Management, ICAP Equities and Tudor. Randeep trained as a Vascular and General Surgeon and read both Medicine and Computer Science at Cambridge University.

Linkedin

Clare is a chartered governance professional with 35 years’ experience in banking and financial services. Clare is Chairman of Fidelity Asian Values plc and a non-executive director of The Golden Charter Trust Limited. She is also non-executive director, Audit Committee Chairman and member of the Risk Committee and Conflicts Committee of M&G Group Limited, M&G Investment Management Limited and M&G Alternatives Investment Management Limited. Clare was a non-executive director of Credit Suisse until its merger with UBS. In her executive career, she was a Director of the International Monetary Fund (“IMF”) and prior to that, the Auditor General at the World Bank, based in Washington D.C. Previously, Clare headed audit and compliance functions at the Bank of England, Barclays Capital, HSBC and Deutsche Bank.

Kate Bolsover worked in the City of London for over 25 years, initially as an analyst and thereafter running the mutual fund businesses of both Baring Asset Management and Cazenove Fund Management. Latterly, she was appointed Director of Corporate Communications for JPMorgan Cazenove. Kate is Chairman of TR Property Investment Trust and an independent director at Baillie Gifford & Co. Kate was also previously non-executive director of JPMorgan American Investment Trust plc and Montanaro UK Smaller Companies Trust plc, and Chairman of both Invesco Enhanced Income Trust plc and Fidelity Asian Values plc.

Linkedin

Josephine is a chartered accountant who sits on the board of Alliance Witan plc. Jo has previously held senior positions within the NatWest Group and was Finance Director of Newcastle United plc. She was Commercial Director, UK, Europe and the Middle East at Serco Group and sat on various advisory boards in the education and charity sector. Jo was also previously Chair of JPMorgan European Growth and Income PLC, and non-executive director and Chair of the Audit Committee of Strategic Equity Capital PLC.

Sarah has over twenty years of fund management experience based in both London and Hong Kong, managing unit trusts and institutional assets. She was formerly a Director of Baring Asset Management (Asia) Ltd in Hong Kong, Asian Investment Manager at Kleinwort Benson Investment Management and Eagle Star in London. She is currently Chair of Schroder Asian Total Return Investment Company plc, Senior Independent Director on the Board of Fidelity Japan Trust plc and a non-executive director of Baillie Gifford China Growth Trust plc. Until March 2024 Sarah was Chair of JPMorgan Multi-Asset Growth and Income plc and Senior Independent Director of abrdn China Investment Company Ltd.

Prof. Tony Young is a practicing frontline NHS surgeon, Associate Medical Director at the Mid and South Essex University Hospitals Group, Director of Medical Innovation at Anglia Ruskin University. In 2014 he was appointed as National Clinical Director for Innovation at NHS England and in February 2016 became the first National Clinical Lead for Innovation and played a leading role in coordinating the NHS response to the COVID-19 pandemic. In 2015 he founded the NHS Clinical Entrepreneur programme. In 2019 Tony was awarded the OBE for services to clinical leadership.

Linkedin

Paul Southgate is a London-based Portfolio Manager at Pictet Asset Management, with over 21 years’ investment experience, including healthcare companies. Before joining Pictet, he was a Managing Partner at Eisenstat Capital Partners (ECAP) and managed European Equities for both Deephaven Capital and Fortress Investments Group. He began his career with UBS Asset Management.

Linkedin

Co-portfolio manager Paul Major has 26 years of experience in the healthcare sector.  He was a top-rated healthcare research analyst and was one of the first research partners at Redburn, Europe’s leading independent research firm. His work there included healthcare portfolio construction projects for several institutions. Paul’s career started in corporate finance at UBS.  He studied biochemistry at Bath University.

Linkedin

Co-portfolio manager Brett Darke has 21 years of experience including 11 years covering healthcare and the wider life sciences sector on the buy-side at TT International, on both long-only and long/short funds. Brett previously worked for five years in healthcare corporate finance at Merrill Lynch and Bear Stearns. He studied medicine and management at Cambridge University.

Linkedin

Paul Major has 26 years of experience in the healthcare sector.  He was a top-rated healthcare research analyst and was one of the first research partners at Redburn, Europe’s leading independent research firm. His work there included healthcare portfolio construction projects for several institutions. Paul’s career started in corporate finance at UBS.  He studied biochemistry at Bath University.

Claude Mikkelsen is Director Investor Relations for BB Biotech. Before that, he served as interim Finance Director at Ecron Acunova after his position as Senior Vice President Finance & Investor Relations at Pharmexa. Claude Mikkelsen has a master’s degree in Economics and Law from Aalborg University and has studied at INSEAD in France.

Markus Peter joined Bellevue Asset Management in early 2009 as head investments and products. He previously held several management positions during his 10 years with Julius Baer Group, including head product management and development, investment advisory as well as a product specialist for absolute return products. Prior to joining Julius Baer he was employed by IBM, treasury and project finance, as well as by Swiss Bank Corporation, equity and equity derivative trading. Markus Peter holds a master in business economics from the University of St. Gallen (HSG).